Testing how well TNF medicines work in inflammatory arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 18 years
- Have been diagnosed with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
- Be about to start infliximab or adalimumab (adalimumab)
- You may also take a conventional DMARD or low-to-moderate steroid (glucocorticoid)
- At the time they collect samples, you should not be starting any new biologic arthritis medicine (bDMARD)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to find which of four biologic drugs works best for you if methotrexate didn't help or caused side effects. You'll get each drug in turn and track your symptoms to find your best match.
This trial tests whether plant-based compounds similar to cannabis (called phytocannabinoids) can help calm inflammation and improve immune function in people with certain types of arthritis or autoimmune diseases like lupus or Sjögren's disease. It aims to offer a new way to treat these conditions without the 'high' of marijuana.
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
Hear when a new Arthritis, Rheumatoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.